Lawrence Kingsley - IDEXX Laboratories Independent Director
IDXX Stock | USD 492.76 12.58 2.49% |
Director
Mr. Lawrence D. Kingsley is Lead Independent Director of the IDEXX Laboratories, Inc. Mr. Kingsley served as Chairman of Pall Corporation from 2013 to 2015 and as Chief Executive Officer of Pall Corporation from 2011 to 2015, and he has served as an Advisory Director to Berkshire Partners LLC, a Bostonbased investment firm, since spring of 2016. Before his experience at Pall, Mr. Kingsley was the Chief Executive Officer of IDEX Corporationrationration, a company specializing in fluid and metering technologies, health and science technologies as well as fire, safety and other diversified products, from 2005 to 2011, and the Chief Operating Officer of IDEX from August 2004 to March 2005. From 1995 to 2004, he held various positions at Danaher Corporation of increasing responsibility, including Corporationrationrate Vice President and Group Executive from March 2004 to August 2004, President of Industrial Controls Group from April 2002 to July 2004, and President of Motion Group, Special Purpose Systems, from January 2001 to March 2002. Mr. Kingsley holds an undergraduate degree in Industrial Engineering and Management from Clarkson University and an M.B.A. from the College of William and Mary. As the former chief executive officers of Pall Corporation and IDEX Corporationrationration, Mr. Kingsley successfully led hightechnology, highgrowth, multinational public companies and demonstrated his leadership and outstanding executive management and operational skills. Mr. Kingsley also brings strategic planning and financial expertise. Mr. Kingsleys experience serving on other public company boards brings additional valuable perspectives to his Board service, including as our independent Lead Director. since 2018.
Age | 55 |
Tenure | 6 years |
Professional Marks | MBA |
Address | One IDEXX Drive, Westbrook, ME, United States, 04092 |
Phone | 207 556 0300 |
Web | https://www.idexx.com |
IDEXX Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.2283 % which means that it generated a profit of $0.2283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.8074 %, meaning that it created $0.8074 on every $100 dollars invested by stockholders. IDEXX Laboratories' management efficiency ratios could be used to measure how well IDEXX Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IDEXX Laboratories' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.27 in 2024, whereas Return On Capital Employed is likely to drop 0.26 in 2024. At this time, IDEXX Laboratories' Return On Assets are fairly stable compared to the past year.Similar Executives
Showing other executives | DIRECTOR Age | ||
Vicky Gregg | Acadia Healthcare | 63 | |
Michael Michelson | HCA Holdings | 69 | |
Chris Gordon | Acadia Healthcare | 44 | |
Charles Holliday | HCA Holdings | 73 | |
Robert Dennis | HCA Holdings | 67 | |
Hartley Rogers | Acadia Healthcare | 56 | |
Christopher Gordon | Acadia Healthcare | 44 | |
Reeve Waud | Acadia Healthcare | 54 | |
Wayne Riley | HCA Holdings | 61 | |
EPerot Bissell | Acadia Healthcare | 58 | |
John Rowe | HCA Holdings | 72 | |
William Petrie | Acadia Healthcare | 71 | |
Kyle Lattner | Acadia Healthcare | 29 | |
Michael Gaynor | Novo Integrated Sciences | 49 | |
Geoffrey Meyers | HCA Holdings | 73 | |
Wade Miquelon | Acadia Healthcare | 53 | |
William Grieco | Acadia Healthcare | 64 | |
Meg Crofton | HCA Holdings | 67 | |
NancyAnn DeParle | HCA Holdings | 64 | |
Jay Light | HCA Holdings | 74 | |
Annie Lamont | HCA Holdings | 60 |
Management Performance
Return On Equity | 0.81 | ||||
Return On Asset | 0.23 |
IDEXX Laboratories Leadership Team
Elected by the shareholders, the IDEXX Laboratories' board of directors comprises two types of representatives: IDEXX Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IDEXX. The board's role is to monitor IDEXX Laboratories' management team and ensure that shareholders' interests are well served. IDEXX Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IDEXX Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
Kathy Turner, Corporate Vice President | ||
Sophie Vandebroek, Director | ||
Jonathan Ayers, Chairman, CEO and Pres | ||
William End, Lead Independent Director | ||
Jacqueline Studer, Corporate Vice President General Counsel, Secretary | ||
Johnny Powers, Executive VP | ||
Rebecca Henderson, Independent Director | ||
Michael Lane, Corporate Vice President General Manager | ||
Anne Szostak, Independent Director | ||
George Fennell, Senior Officer | ||
Sharon Underberg, Corporate Vice President General Counsel, and Corporate Secretary | ||
Ken Grady, Senior Officer | ||
Jay Mazelsky, Executive VP | ||
Stuart Essig, Independent Director | ||
M Szostak, Independent Director | ||
Bruce Claflin, Independent Director | ||
Sam Samad, Independent Director | ||
Barry Johnson, Independent Director | ||
Giovani Twigge, Chief Human Resource Officer, Corporate Vice President | ||
Nimrata PE, Sector Strategy | ||
Martin Smith, Executive CTO | ||
Jeffery Chadbourne, Director Reporting | ||
Daniel Junius, Independent Director | ||
Lawrence Kingsley, Independent Director | ||
Kerry Bennett, Senior Labs | ||
Thomas Craig, Independent Director | ||
Michael Johnson, Executive Officer | ||
Jonathan Mazelsky, CEO President | ||
James Polewaczyk, Executive Officer | ||
John Hart, Senior Operations | ||
Michael Williams, Executive VP | ||
Pat Venters, Chief Marketing Officer, Vice President | ||
Brian McKeon, CFO, Principal Accounting Officer, Executive VP and Treasurer |
IDEXX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IDEXX Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.81 | ||||
Return On Asset | 0.23 | ||||
Profit Margin | 0.23 % | ||||
Operating Margin | 0.27 % | ||||
Current Valuation | 42.6 B | ||||
Shares Outstanding | 83.05 M | ||||
Shares Owned By Insiders | 0.92 % | ||||
Shares Owned By Institutions | 92.05 % | ||||
Number Of Shares Shorted | 1.71 M | ||||
Price To Earning | 61.31 X |
IDEXX Laboratories Investors Sentiment
The influence of IDEXX Laboratories' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in IDEXX. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to IDEXX Laboratories' public news can be used to forecast risks associated with an investment in IDEXX. The trend in average sentiment can be used to explain how an investor holding IDEXX can time the market purely based on public headlines and social activities around IDEXX Laboratories. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
IDEXX Laboratories' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for IDEXX Laboratories' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average IDEXX Laboratories' news discussions. The higher the estimated score, the more favorable is the investor's outlook on IDEXX Laboratories.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards IDEXX Laboratories in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, IDEXX Laboratories' short interest history, or implied volatility extrapolated from IDEXX Laboratories options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for IDEXX Stock analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is IDEXX Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IDEXX Laboratories. If investors know IDEXX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IDEXX Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.121 | Earnings Share 10.06 | Revenue Per Share 44.073 | Quarterly Revenue Growth 0.088 | Return On Assets 0.2283 |
The market value of IDEXX Laboratories is measured differently than its book value, which is the value of IDEXX that is recorded on the company's balance sheet. Investors also form their own opinion of IDEXX Laboratories' value that differs from its market value or its book value, called intrinsic value, which is IDEXX Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IDEXX Laboratories' market value can be influenced by many factors that don't directly affect IDEXX Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IDEXX Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if IDEXX Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IDEXX Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.